12/9
08:19 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
12/8
11:41 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
12/8
07:03 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/8
07:00 am
ocul
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
High
Report
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
12/6
09:27 am
ocul
Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD [Yahoo! Finance]
High
Report
Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD [Yahoo! Finance]
12/5
07:00 am
ocul
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/25
08:07 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
11/24
07:00 am
ocul
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
Low
Report
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
11/24
02:05 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) was upgraded by analysts at
Wall Street
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) was upgraded by analysts at
Wall Street
11/18
12:49 am
ocul
Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences [Yahoo! Finance]
Low
Report
Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences [Yahoo! Finance]
11/16
01:10 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) was downgraded by analysts at
Wall Stre
Medium
Report
Ocular Therapeutix (NASDAQ:OCUL) was downgraded by analysts at
Wall Stre
11/14
11:21 am
ocul
Will Ocular Therapeutix's (OCUL) SOL-R Enrollment Success Offset Weaker Financials in the Long Run? [Yahoo! Finance]
Low
Report
Will Ocular Therapeutix's (OCUL) SOL-R Enrollment Success Offset Weaker Financials in the Long Run? [Yahoo! Finance]
11/14
01:20 am
ocul
Ocular Therapeutix Stock Earns 81 RS Rating [Yahoo! Finance]
Low
Report
Ocular Therapeutix Stock Earns 81 RS Rating [Yahoo! Finance]
11/12
07:00 am
ocul
Ocular Therapeutix™ to Participate in November and December Investor Conferences
Low
Report
Ocular Therapeutix™ to Participate in November and December Investor Conferences
11/7
07:00 am
ocul
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/5
03:07 pm
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
11/5
08:07 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
11/4
07:05 am
ocul
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
Medium
Report
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
11/4
07:00 am
ocul
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
Medium
Report
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
10/30
04:14 pm
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its price target raised by analysts at TD Cowen from $14.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its price target raised by analysts at TD Cowen from $14.00 to $20.00. They now have a "buy" rating on the stock.
10/30
10:07 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
10/28
07:00 am
ocul
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
Low
Report
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
10/24
08:38 pm
ocul
Ocular Therapeutix (OCUL) Valuation in Focus Following Recent Share Price Moves [Yahoo! Finance]
Low
Report
Ocular Therapeutix (OCUL) Valuation in Focus Following Recent Share Price Moves [Yahoo! Finance]
10/17
10:06 pm
ocul
H.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy Rating [Yahoo! Finance]
Medium
Report
H.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy Rating [Yahoo! Finance]
10/13
06:07 pm
ocul
Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Advancements | DelveInsight [Yahoo! Finance]
Medium
Report
Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Advancements | DelveInsight [Yahoo! Finance]